Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors
- PMID: 17274611
- DOI: 10.1021/ci600320q
Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors
Abstract
A structure-based molecular modeling approach was performed to identify novel structural characteristics and scaffolds that might represent new classes of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). The software LigandScout was used for identification and visualization of protein-ligand interaction sites and pharmacophore model generation. In the next step virtual screening of 3D multiconformational databases together with docking experiments allowed the identification of promising candidates for biological testing. The positive biological results obtained confirm the validity of our work strategy.
Similar articles
-
HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.J Med Chem. 2005 Jan 13;48(1):200-12. doi: 10.1021/jm0493921. J Med Chem. 2005. PMID: 15634014
-
Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa.J Chem Inf Model. 2005 Jan-Feb;45(1):146-59. doi: 10.1021/ci049778k. J Chem Inf Model. 2005. PMID: 15667140
-
A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.Proteins. 2004 Feb 15;54(3):526-33. doi: 10.1002/prot.10599. Proteins. 2004. PMID: 14748000
-
Pyridin-2(1H)-ones: a promising class of HIV-1 non-nucleoside reverse transcriptase inhibitors.ChemMedChem. 2007 Aug;2(8):1141-7. doi: 10.1002/cmdc.200700054. ChemMedChem. 2007. PMID: 17477343 Review. No abstract available.
-
Novel HIV-1 reverse transcriptase inhibitors.Virus Res. 2008 Jun;134(1-2):171-85. doi: 10.1016/j.virusres.2008.01.003. Epub 2008 Mar 4. Virus Res. 2008. PMID: 18308412 Review.
Cited by
-
Identification of 3-((1-(Benzyl(2-hydroxy-2-phenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamoyl)pyrazine-2-carboxylic Acid as a Potential Inhibitor of Non-Nucleosidase Reverse Transcriptase Inhibitors through InSilico Ligand- and Structure-Based Approaches.Molecules. 2021 Aug 30;26(17):5262. doi: 10.3390/molecules26175262. Molecules. 2021. PMID: 34500699 Free PMC article.
-
Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors.J Mol Model. 2010 Jul;16(7):1195-204. doi: 10.1007/s00894-009-0630-y. Epub 2009 Dec 18. J Mol Model. 2010. PMID: 20020310
-
Virtual screening for the discovery of bioactive natural products.Prog Drug Res. 2008;65:211, 213-49. doi: 10.1007/978-3-7643-8117-2_6. Prog Drug Res. 2008. PMID: 18084917 Free PMC article. Review.
-
From laptop to benchtop to bedside: structure-based drug design on protein targets.Curr Pharm Des. 2012;18(9):1217-39. doi: 10.2174/138161212799436386. Curr Pharm Des. 2012. PMID: 22316152 Free PMC article. Review.
-
Identification of Sclareol As a Natural Neuroprotective Cav 1.3-Antagonist Using Synthetic Parkinson-Mimetic Gene Circuits and Computer-Aided Drug Discovery.Adv Sci (Weinh). 2022 Mar;9(7):e2102855. doi: 10.1002/advs.202102855. Epub 2022 Jan 18. Adv Sci (Weinh). 2022. PMID: 35040584 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources